Cell Signaling Technology

TORC3/CRTC3 Antibody

#2768 · $394

62
Evidence Score · Well-Established
Used by 191 independent labs across 200 papers. How we score this →
100
Citing papers
12.7k
Combined citations
Supplier page Find this product

Research areas

Angiogenesis and VEGF in Cancer8Cell Adhesion Molecules Research8MicroRNA in disease regulation8Cancer Cells and Metastasis6Immune cells in cancer5Signaling Pathways in Disease5Retinal Development and Disorders5Genomics, phytochemicals, and oxidative stress4

Papers citing this product

1
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>
Cancer Science·2011·519 cit.·DOI
2
Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke
Nature Communications·2020·511 cit.·DOI
3
Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB
Scientific Reports·2014·340 cit.·DOI
4
Non-viral precision T cell receptor replacement for personalized cell therapy
Nature·2022·276 cit.·DOI
5
Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps
Developmental Cell·2017·274 cit.·DOI
6
The SARS Coronavirus 3a Protein Causes Endoplasmic Reticulum Stress and Induces Ligand-Independent Downregulation of the Type 1 Interferon Receptor
PLoS ONE·2009·271 cit.·DOI
7
Microglia promote colonization of brain tissue by breast cancer cells in a Wnt‐dependent way
Glia·2010·242 cit.·DOI
8
Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling
International Journal of Nanomedicine·2016·228 cit.·DOI
9
Galectin-3 Protein Modulates Cell Surface Expression and Activation of Vascular Endothelial Growth Factor Receptor 2 in Human Endothelial Cells
Journal of Biological Chemistry·2011·216 cit.·DOI
10
Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages
Journal of Experimental & Clinical Cancer Research·2022·211 cit.·DOI

Similar products

ProductVendorEvidencePricePapers
TORC3/CRTC3 (C35G4) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology62$161,351100

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.